ML23223A087

From kanterella
Jump to navigation Jump to search
Notice of Closed Meeting with Terumo on August 31, 2023
ML23223A087
Person / Time
Issue date: 08/11/2023
From:
NRC/NMSS/DMSST/MSEB
To:
Celimar Valentin-Rodriguez
References
Download: ML23223A087 (3)


Text

NON-

PUBLIC MEETING ANNOUNCEMENT

Title:

Closed Meeting with Terumo Medical Corporation Date(s) and Time(s): August 31, 2023, 10:00 AM to 11:30 AM ET Location:

TWFN-5D30 Category:

This is a closed meeting. This meeting is closed to the public because proprietary design and use information will be discussed during the meeting.

Purpose:

The purpose of this meeting is to have discussions with Terumo Medical Corporation (Terumo) regarding Terumos microsphere technology, QuiremSpheres, which are holmium-166 microspheres for the treatment of unresectable liver tumors.

Contact:

Celimar Valentin-Rodriguez 301-415-7124 celimar.valentin-rodriguez@nrc.gov

Participants:

NRC Office of Nuclear Material Safety and Safeguards External Terumo Medical Corporation Orchestra Life Sciences

NON-

PUBLIC MEETING AGENDA

Closed Meeting with Terumo Medical Corporation August 31, 2023, 10:00 AM to 11:30 AM ET TWFN-5D30 Time Topic Speaker 10:00 -

11:30 AM Introductions and opening remarks Overview of QuiremSpheres Discussion NRC/Terumo Terumo NRC/Terumo

The time of the meeting is local to the jurisdiction where the meeting is being held.

The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If reasonable accommodation is needed to participate in this meeting, or if a meeting notice, transcript, or other information from this meeting is needed in another format (e.g., Braille, large print), please notify the NRC meeting contact.

Determinations on requests for reasonable accommodation will be made on a case-by-case basis.

ADAMS Accession Number: ML23223A087 OFFICIAL RECORD COPY Link to meeting details:

Commission's Policy Statement on "Enhancing Public Participation in NRC Meetings" 86 Federal Register 14964, March 19, 2021 The policy statement may be found at https://www.govinfo.gov/content/pkg/FR-2021-03-19/pdf/2021-05787.pdf